Cancer-Killing Virus Armed with Antimicrobial Peptide β-Defensin 2 Boosts Anti-Tumor Immunity | Research

The takeaway

An oncolytic virus engineered to produce the antimicrobial peptide β-defensin 2 recruited immune cells to tumors and significantly inhibited melanoma growth and metastasis in mice.

Dual anti-tumor mechanism
The HBD2-armed virus both kills tumor cells directly (oncolysis) and recruits the immune system via dendritic cell chemotaxis, creating a two-pronged attack against cancer.

What the researchers found

A recombinant oncolytic vaccinia virus engineered to express human β-defensin 2 (HBD2) — an antimicrobial peptide of the innate immune system — significantly inhibited tumor growth and metastasis in a mouse melanoma model. The HBD2-expressing virus recruited plasmacytoid dendritic cells to the tumor site, which then activated both CD4+ and CD8+ tumor-infiltrating T cells. This triggered both innate and adaptive immune responses against the cancer.

Why it matters

This study demonstrates an innovative approach: using an antimicrobial peptide (HBD2) not to fight infection, but to fight cancer. By engineering a cancer-killing virus to also produce this immune-stimulating peptide, researchers created a dual-action therapy that both destroys tumor cells directly and recruits the immune system. It represents a creative cross-application of peptide biology from infectious disease to oncology.

The numbers in context

VV-HBD2-lacZ construct · HBD2 attracted dendritic cells in vitro and in vivo · increased CD4+ and CD8+ T cells in tumors · significantly inhibited tumor growth and metastasis · mouse melanoma model

How the study worked

Researchers constructed a recombinant vaccinia virus (VV-HBD2-lacZ) expressing human β-defensin 2. They tested HBD2's ability to attract dendritic cells in vitro and in vivo, then evaluated anti-tumor effects in a mouse melanoma model. Tumor growth, metastasis, and immune cell infiltration (CD4+ and CD8+ T cells) were assessed.

Who was studied

Mouse melanoma cancer model (in vivo) and cell culture studies (in vitro)

What this study cannot tell us

This is a preclinical mouse study using a melanoma model, which may not translate directly to human cancers. The long-term safety of using an oncolytic virus expressing a human antimicrobial peptide was not assessed. The study did not compare the HBD2-expressing virus to other immunostimulatory gene insertions. Potential off-target immune activation by HBD2 was not fully evaluated.

How to read the evidence

This is a preclinical proof-of-concept study in a mouse melanoma model. The results are promising and the experimental design is sound, but validation in additional cancer models and eventually human studies is needed before clinical application.

When this study was published

Published in 2019, this study represents an innovative approach to combining peptide immunology with oncolytic virotherapy that has continued to gain research attention.

The bigger picture

This study sits at the intersection of three hot research areas: oncolytic virotherapy, antimicrobial peptides, and cancer immunotherapy. It demonstrates that antimicrobial peptides can serve as immunological bridges, using their chemotactic properties to recruit immune cells to tumors. As oncolytic virus therapies advance through clinical trials, arming them with immune-stimulating peptides like defensins could enhance their anti-cancer effectiveness.

Questions still open

Would HBD2-expressing oncolytic viruses be effective against cancer types other than melanoma?
Could other antimicrobial peptides (like LL-37 or α-defensins) be even more effective than HBD2 when delivered via oncolytic viruses?
How does the anti-tumor immune response from HBD2-armed virus compare to established checkpoint inhibitor immunotherapy?

Common questions

What is β-defensin 2 and why does it help fight cancer?

β-defensin 2 (HBD2) is an antimicrobial peptide naturally produced by the body to fight infections. It works partly by attracting immune cells called dendritic cells to sites of danger. In this study, when tumor cells were engineered to produce HBD2, it recruited dendritic cells to the tumor, which then activated cancer-killing T cells. Essentially, the peptide tricked the immune system into treating the tumor like an infection.

What is an oncolytic virus and how does adding a peptide improve it?

Oncolytic viruses are engineered or naturally occurring viruses that selectively infect and kill cancer cells while leaving normal cells unharmed. On their own, they can shrink tumors, but the immune response they generate is often not strong enough for lasting remission. By inserting the gene for β-defensin 2, the virus produces an immune-recruiting peptide as it kills cancer cells, amplifying the immune response and creating a more durable anti-cancer effect.

Read the original research

Recombinant Oncolytic Vaccinia Viruses Expressing Human β-Defensin 2 Enhance Anti-tumor Immunity.

Molecular therapy oncolytics, 13, 49-57

View on PubMed ↗Publisher’s paper ↗

Citation

Sun, Ting; Luo, Yanxi; Wang, Minglong; Xie, Tian; Yan, Hui. (2019). Recombinant Oncolytic Vaccinia Viruses Expressing Human β-Defensin 2 Enhance Anti-tumor Immunity.. Molecular therapy oncolytics, 13, 49-57. https://doi.org/10.1016/j.omto.2019.03.010